journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/30181425/being-critical-of-critical-care-given-to-people-with-metastatic-cancer-get-palliative-care-involved
#1
Talha Mehmood, Thomas J Smith
No abstract text is available yet for this article.
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181424/resurrection-of-parp-inhibitors-in-breast-cancer
#2
REVIEW
Tomas G Lyons, Mark E Robson
PARP enzymes are essential for DNA damage repair. Cancers with defective homologous recombination DNA repair, such has BRCA1 - and BRCA2 -mutated breast cancers, are targets for PARP inhibitors (PARPi) through the exploitation of synthetic lethality. A number of PARPi are currently undergoing clinical evaluation in breast cancer, with olaparib and talazoparib having demonstrated superior efficacy compared with standard chemotherapy in advanced germline BRCA -mutated cancer. This review describes the biological rationale for PARPi and presents the accumulating data on PARPi use in breast cancer...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181423/management-of-primary-ovarian-insufficiency-symptoms-in-survivors-of-childhood-and-adolescent-cancer
#3
REVIEW
Emma Gargus, Rebecca Deans, Antoinette Anazodo, Teresa K Woodruff
Cancer treatments can damage the ovaries, causing primary ovarian insufficiency (POI), a condition associated with numerous sequelae that impact long-term quality of life. This article systematically reviews the literature on the prevalence, surveillance, and treatment of POI in survivors of pediatric and adolescent and young adult (AYA) cancers. A systematic review of the literature was conducted in January 2018 through a search of Medline, Embase, Web of Science, and SCOPUS, alongside the screening of relevant reference lists...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181422/chronic-myeloid-leukemia-version-1-2019-nccn-clinical-practice-guidelines-in-oncology
#4
Jerald P Radich, Michael Deininger, Camille N Abboud, Jessica K Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M Kantarjian, Lori Maness, Leland Metheny, Joseph O Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G Rose, Neil P Shah, B Douglas Smith, David S Snyder, Kendra L Sweet, Moshe Talpaz, James Thompson, David T Yang, Kristina M Gregory, Hema Sundar
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181421/chimeric-antigen-receptor-t-cell-therapy
#5
Ndiya Ogba, Nicole M Arwood, Nancy L Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J Fry, Morgan Garber, Rebecca A Gardner, Lauren Gurschick, Patricia Kropf, Jeff J Reitan, Craig Sauter, Bijal Shah, Elizabeth J Shpall, Steven T Rosen
Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181420/impact-of-nonconcordance-with-nccn-guidelines-on-resource-utilization-cost-and-mortality-in-de-novo-metastatic-breast-cancer
#6
Gabrielle B Rocque, Courtney P Williams, Bradford E Jackson, Stacey A Ingram, Karian I Halilova, Maria Pisu, Kelly M Kenzik, Andres Azuero, Andres Forero, Smita Bhatia
Background: The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) have directed the care of patients with cancer for >20 years. Payers are implementing guideline-based pathway programs that restrict reimbursement for non-guideline-based care to control costs, yet evidence regarding impact of guidelines on outcomes, including mortality, Medicare costs, and healthcare utilization, is limited. Patients and Methods: This analysis evaluated concordance of first treatment with NCCN Guidelines for women with de novo stage IV metastatic breast cancer (MBC) included within the SEER-Medicare linked database and diagnosed between 2007 and 2013...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181419/benchmarking-cancer-centers-from-care-pathways-to-integrated-practice-units
#7
Anke Wind, Francisco Rocha Gonçalves, Edit Marosi, Lucia da Pieve, Monica Groza, Marco Asioli, Marco Albini, Wim van Harten
Background: Structuring cancer care into pathways can reduce variability in clinical practice and improve patient outcomes. International benchmarking can help centers with regard to development, implementation, and evaluation. A further step in the development of multidisciplinary care is to organize care in integrated practice units (IPUs), encompassing the whole pathway and relevant organizational aspects. However, research on this topic is limited. This article describes the development and results of a benchmark tool for cancer care pathways and explores IPU development in cancer centers...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181418/ability-to-predict-new-onset-psychological-distress-using-routinely-collected-health-data-a-population-based-cohort-study-of-women-diagnosed-with-breast-cancer
#8
Ania Syrowatka, James A Hanley, Daniala L Weir, William G Dixon, Ari N Meguerditchian, Robyn Tamblyn
Objectives: The primary objective of this study was to identify the predictors of new-onset psychological distress available in routinely collected administrative health databases for women diagnosed with breast cancer. The secondary objective was to explore whether the predictors vary based on the period of cancer care. Methods: A population-based cohort study followed 16,495 female patients with newly diagnosed breast cancer who did not experience psychological distress during the 14 months before breast cancer surgery...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181417/use-of-inpatient-palliative-care-services-in-patients-with-advanced-cancer-receiving-critical-care-therapies
#9
Kah Poh Loh, Maya Abdallah, Meng-Shiou Shieh, Mihaela S Stefan, Penelope S Pekow, Peter K Lindenauer, Supriya G Mohile, Dilip Babu, Tara Lagu
Background: Invasive mechanical ventilation (IMV), dialysis for acute kidney failure, and other critical care therapies (CCTs) are associated with a high risk for complications in patients with metastatic cancer. Inpatient palliative care (IPC) can assist in assessing patients' preferences for life-prolonging treatment at the end of life. This study investigated the use pattern of IPC, outcomes (in-hospital mortality, length of stay [LOS], discharge destination, and cost of care), and predictors of IPC use in patients with metastatic cancer who received CCTs...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181416/nccn-guidelines-insights-bladder-cancer-version-5-2018
#10
Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Tracy M Downs, Jason A Efstathiou, Terence Friedlander, Richard E Greenberg, Khurshid A Guru, Noah Hahn, Harry W Herr, Christopher Hoimes, Brant A Inman, Masahito Jimbo, A Karim Kader, Subodh M Lele, Joshua J Meeks, Jeff Michalski, Jeffrey S Montgomery, Lance C Pagliaro, Sumanta K Pal, Anthony Patterson, Daniel P Petrylak, Elizabeth R Plimack, Kamal S Pohar, Michael P Porter, Mark A Preston, Wade J Sexton, Arlene O Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A Dwyer, Lisa A Gurski
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181415/targeting-braf-mutations-in-high-grade-neuroendocrine-carcinoma-of-the-colon
#11
Jarred Burkart, Dwight Owen, Manisha H Shah, Sherif R Z Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W Reeser, Eric Samorodnitsky, Amy Smith, Bhavana Konda
Mutations in the RAS/RAF/MEK/ERK pathway leading to constitutive activation and uncontrolled cellular growth have been identified in various human malignancies, making this pathway a target for potential therapeutics. The activating BRAF V600E mutation is one well-characterized oncogenic mutation that has been described and targeted with clinical success in various malignancies, including melanoma and hairy cell leukemia. Although BRAF -directed treatments have yielded clinical benefit in a subset of tumor types, such as melanoma, thyroid cancer, and lung cancer, BRAF inhibition fails to confer a clinical benefit in colon cancer...
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181414/letter-to-the-editor-significance-of-clonal-hematopoiesis-of-indeterminate-potential
#12
LETTER
Steven Sorscher, Lydia Usha, Kelly Burgess, Oleksandra Klapko, Lela Buckingham
No abstract text is available yet for this article.
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30181413/getting-what-you-pay-for-finding-value-in-cancer-care
#13
Margaret Tempero
No abstract text is available yet for this article.
September 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099377/does-chemoradiation-benefit-patients-with-gastric-cancer-managed-without-surgery
#14
Kimberly L Johung, Stacey M Stein
No abstract text is available yet for this article.
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099376/evolving-paradigms-in-hiv-malignancies-review-of-ongoing-clinical-trials
#15
REVIEW
Rachel Bender Ignacio, Lilie L Lin, Lakshmi Rajdev, Elizabeth Chiao
This review highlights current interventional clinical trials for HIV-associated malignancies (HIVAMs), with emphasis on 4 mechanistic areas: immunomodulatory therapies and gene therapies, including immune checkpoint inhibitors; cytotoxic therapies; novel tumor-targeted and virally targeted therapies in both AIDS-defining and non-AIDS-defining cancers (NADC); and other screening or topical/ablative interventions. A search on ClinicalTrials.gov located 35 trials, including 12 immunomodulatory or gene therapy trials, 6 cytotoxic therapy trials, 10 trials of therapies with tumor or viral molecular targets, and 7 trials evaluating screening interventions or topical or ablative therapies...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099375/cancer-in-people-living-with-hiv-version-1-2018-nccn-clinical-practice-guidelines-in-oncology
#16
Erin Reid, Gita Suneja, Richard F Ambinder, Kevin Ard, Robert Baiocchi, Stefan K Barta, Evie Carchman, Adam Cohen, Neel Gupta, Kimberly L Johung, Ann Klopp, Ann S LaCasce, Chi Lin, Oxana V Makarova-Rusher, Amitkumar Mehta, Manoj P Menon, David Morgan, Nitya Nathwani, Ariela Noy, Frank Palella, Lee Ratner, Stacey Rizza, Michelle A Rudek, Jeff Taylor, Benjamin Tomlinson, Chia-Ching J Wang, Mary A Dwyer, Deborah A Freedman-Cass
People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has led to substandard cancer care being offered to PLWH. To fill that gap, the NCCN Guidelines for Cancer in PLWH were developed; they provide treatment recommendations for PLWH who develop non-small cell lung cancer, anal cancer, Hodgkin lymphoma, and cervical cancer...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099374/determinants-and-outcomes-of-satisfaction-with-healthcare-provider-communication-among-cancer-survivors
#17
Ashish Rai, Xuesong Han, Zhiyuan Zheng, K Robin Yabroff, Ahmedin Jemal
Background: Despite the surge of interest in improving provider communication, empirical research is sparse on the determinants and outcomes of cancer survivors' satisfaction with healthcare provider communication. Methods: Longitudinal Medical Expenditure Panel Survey data spanning 2008 through 2014 was used to identify 4,588 respondents who were ever diagnosed with cancer. A composite score was generated by combining 5 measures of satisfaction. We used multivariate logistic regressions and 2-part models to examine the associations between satisfaction ratings and outcomes, including general, mental, and physical health; office visits; and total healthcare, drug, and out-of-pocket expenditures...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099373/genomic-profiling-in-patients-with-malignant-peripheral-nerve-sheath-tumors-reveals-multiple-pathways-with-targetable-mutations
#18
Henry G Kaplan, Steven Rostad, Jeffrey S Ross, Siraj M Ali, Sherri Z Millis
Background: The aim of this study was to determine the frequency of alterations in BRAF and other RAS/RAF genes, as well as other targetable pathways in malignant peripheral nerve sheath tumors (MPNSTs). Patients and Methods: Pathology specimens were available for 2 cohorts: (1) patients with MPNST at Swedish Cancer Institute (n=17) from 2004 through 2016, and (2) patients with MPNST evaluated for >300 genomic alterations at Foundation Medicine from 2014 through 2016 (n=186; including 2 Swedish patients with BRAF -mutated MPNST)...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099372/swedish-version-of-the-distress-thermometer-validity-evidence-in-patients-with-colorectal-cancer
#19
Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E Pettersson, Richard Sawatzky
Background: The objective of this study was to validate the NCCN Distress Thermometer (DT), including the accompanying Problem List (PL), in a Swedish population of patients diagnosed with colorectal cancer (CRC). Methods: A total of 488 patients diagnosed with CRC completed the DT/PL and EORTC core quality-of-life questionnaire (QLQ-C30) before surgery. Construct validity of the PL was analyzed using a confirmatory factor analysis. Internal consistency reliability (ICR) was tested using Cronbach's alpha coefficient...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/30099371/chemoradiation-improves-survival-compared-with-chemotherapy-alone-in-unresected-nonmetastatic-gastric-cancer
#20
Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A Nelson, Yi-Jen Chen
Background: Limited data are available to guide management of patients with stage I-III gastric cancer not undergoing potentially curative surgical resection. We compared survival outcomes associated with chemotherapy alone versus chemoradiation (CRT) in the treatment of nonmetastatic gastric cancer. Methods: Patients with gastric adenocarcinoma from 2004 to 2015 were identified using the National Cancer Database. Patients were excluded if they had surgery, metastatic disease, or T0, Tis, or T1a disease. Logistic regression was used to evaluate predictors of CRT use...
August 2018: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"